{"entity":{"id":"nct04853342","kind":"trial","name":"To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy","aka":["FORWARD"],"tldr":"A phase 3 trial of Furmonertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.","summary":"To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy is a phase 3 interventional study registered as NCT04853342 by Allist Pharmaceuticals, Inc., with 318 participants planned, started 2021-06-07 and due to reach its primary completion in 2026-12. Interventions recorded: Drug: Furmonertinib 80 mg and Furmonertinib 80 mg placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04853342","url":"https://clinicaltrials.gov/study/NCT04853342"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","resectable-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["furmonertinib"],"companies":["allist"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04853342","phase":"3","setting":"A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, Study to Assess the Efficacy and Safety of Furmonertinib (AST2818) Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy","sponsor":"Allist Pharmaceuticals, Inc.","participation":[{"nct":"NCT04853342","source":"https://clinicaltrials.gov/study/NCT04853342","fetchedAt":"2026-10-07T16:53:29.376Z","studySha256":"7235e2ca988cd0e97d57daaff5c377832d78214dba3cd8c64b6fc61b9e776879","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-13","leadSponsor":"Allist Pharmaceuticals, Inc.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":318,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2021-06-07","startedType":"actual","enrolled":318,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04853342/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/"}],"company":[{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/"}]}}